Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sonrotoclax by BeiGene for Refractory Multiple Myeloma: Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...
Sonrotoclax by BeiGene for Relapsed Multiple Myeloma: Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase...
Sonrotoclax by BeiGene for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData,...
Sonrotoclax by BeiGene for Mantle Cell Lymphoma: Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
Sonrotoclax by BeiGene for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Zanubrutinib by BeiGene for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
Zanubrutinib by BeiGene for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
BGB-16673 by BeiGene for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to GlobalData,...
BGBA-445 by BeiGene for Nasopharyngeal Cancer: Likelihood of Approval
BGBA-445 is under clinical development by BeiGene and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II...
Lifirafenib maleate by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Lifirafenib maleate by BeiGene for Ovarian Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
BGB-16673 by BeiGene for Marginal Zone B-cell Lymphoma: Likelihood of Approval
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
BGB-16673 by BeiGene for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData,...
BGB-16673 by BeiGene for Mantle Cell Lymphoma: Likelihood of Approval
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
BGB-15025 by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
BGB-15025 is under clinical development by BeiGene and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
BGB-15025 by BeiGene for Gastric Cancer: Likelihood of Approval
BGB-15025 is under clinical development by BeiGene and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
BGB-15025 by BeiGene for Solid Tumor: Likelihood of Approval
BGB-15025 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
BGBA-445 by BeiGene for Nasopharyngeal Cancer: Likelihood of Approval
BGBA-445 is under clinical development by BeiGene and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II...
Lifirafenib maleate by BeiGene for Ovarian Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Ociperlimab by BeiGene for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...